i2o 105s
Alternative Names: i2o-105sLatest Information Update: 15 Jan 2024
At a glance
- Originator i2O Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 31 Aug 2023 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Obesity in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) (i2o Therapeutics pipeline, August 2023)